Overview

Evaluation of the Use of Apixaban in Prevnetion of Thromboembolic Disease in Patients With Myeloma Trated With iMiDs

Status:
Unknown status

Trial end date:
2017-07-01

Target enrollment:

Participant gender:

Summary

To evaluate: - the incidence of venous thromboembolic event (VTE) - the incidence of hemorrhagic complications, In a population of patients with myeloma who are treated with IMiDs and require thromboprophylaxis for 6 months, using an oral anti-Xa anticoagulant, Apixaban, in a preventive scheme, 2.5 mg x2/day

Phase:

Phase 3

Details

Lead Sponsor:

University Hospital, Grenoble

Collaborator:

Celgene Corporation

Treatments:

Anticoagulants
Apixaban
Dalteparin
Heparin, Low-Molecular-Weight